GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 12.78
(-0.47%)
CNY 12.78
(-0.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.15 Billion CNY | 34.45% |
| 2022 | 861.81 Million CNY | 30.19% |
| 2021 | 661.95 Million CNY | 57.14% |
| 2020 | 421.24 Million CNY | -28.0% |
| 2019 | 585.02 Million CNY | 23.8% |
| 2018 | 472.57 Million CNY | 11.37% |
| 2017 | 424.31 Million CNY | 26.78% |
| 2016 | 334.69 Million CNY | 49.82% |
| 2015 | 223.39 Million CNY | 35.08% |
| 2014 | 165.38 Million CNY | 67.72% |
| 2013 | 98.6 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 373.22 Million CNY | 14.01% |
| 2024 Q1 | 288.74 Million CNY | -38.86% |
| 2024 Q2 | 322.46 Million CNY | 11.68% |
| 2023 Q3 | 256.18 Million CNY | 25.33% |
| 2023 Q4 | 472.27 Million CNY | 84.35% |
| 2023 FY | 1.15 Billion CNY | 34.45% |
| 2023 Q1 | 252.66 Million CNY | -29.72% |
| 2023 Q2 | 204.39 Million CNY | -19.1% |
| 2022 Q2 | 188.15 Million CNY | 68.17% |
| 2022 Q1 | 111.88 Million CNY | -50.63% |
| 2022 FY | 861.81 Million CNY | 30.19% |
| 2022 Q4 | 359.5 Million CNY | 77.74% |
| 2022 Q3 | 202.26 Million CNY | 7.5% |
| 2021 Q4 | 226.63 Million CNY | 32.8% |
| 2021 FY | 661.95 Million CNY | 57.14% |
| 2021 Q2 | 175.48 Million CNY | 96.74% |
| 2021 Q1 | 89.19 Million CNY | -50.43% |
| 2021 Q3 | 170.65 Million CNY | -2.75% |
| 2020 Q4 | 179.95 Million CNY | 236.72% |
| 2020 FY | 421.24 Million CNY | -28.0% |
| 2020 Q2 | 89.79 Million CNY | -8.43% |
| 2020 Q1 | 98.06 Million CNY | -51.85% |
| 2020 Q3 | 53.44 Million CNY | -40.48% |
| 2019 Q1 | 95.4 Million CNY | 0.0% |
| 2019 FY | 585.02 Million CNY | 23.8% |
| 2019 Q4 | 203.64 Million CNY | 36.63% |
| 2019 Q3 | 149.04 Million CNY | 8.86% |
| 2019 Q2 | 136.92 Million CNY | 43.51% |
| 2018 FY | 472.57 Million CNY | 11.37% |
| 2018 Q2 | 123.06 Million CNY | 68.27% |
| 2018 Q1 | 73.13 Million CNY | -45.23% |
| 2017 FY | 424.31 Million CNY | 26.78% |
| 2017 Q1 | 55.6 Million CNY | -47.07% |
| 2017 Q3 | 133.54 Million CNY | 0.0% |
| 2017 Q4 | 133.54 Million CNY | 0.0% |
| 2016 Q4 | 105.06 Million CNY | 0.0% |
| 2016 Q1 | 62.28 Million CNY | -8.88% |
| 2016 Q2 | 62.28 Million CNY | -0.0% |
| 2016 Q3 | 105.06 Million CNY | 68.68% |
| 2016 FY | 334.69 Million CNY | 49.82% |
| 2015 Q3 | 68.35 Million CNY | 57.71% |
| 2015 Q1 | 43.34 Million CNY | -6.9% |
| 2015 Q4 | 68.35 Million CNY | 0.0% |
| 2015 Q2 | 43.34 Million CNY | 0.0% |
| 2015 FY | 223.39 Million CNY | 35.08% |
| 2014 Q3 | 46.55 Million CNY | 28.83% |
| 2014 Q1 | 36.13 Million CNY | 0.0% |
| 2014 FY | 165.38 Million CNY | 67.72% |
| 2014 Q2 | 36.13 Million CNY | 0.0% |
| 2014 Q4 | 46.55 Million CNY | 0.0% |
| 2013 FY | 98.6 Million CNY | 0.0% |